Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Expects to Gross $66M in Public Stock Offering

NEW YORK (GenomeWeb News) — Clinical Data expects to gross $66 million in a previously disclosed plan to offer 3 million shares of its common stock. The offering would price the shares at $22 apiece, the company said today.
  
Clinical Data plans to pump some of the proceeds into clinical trials, preclinical R&D, and expenses, acquisitions, and working capital.
 
Chairman Randal Kirk, Clinical Data’s largest shareholder, will buy an aggregate of 2.25 million shares at a cost of $49.5 million. That pickup will leave Kirk holding roughly 48 percent of the company, either directly or through affiliates.
 
The company has granted the underwriters a 30-day option to buy 450,000 additional shares at the public offering price to cover over-allotments. Clinical Data said it expects to close the offering on July 23.
 
Bear, Stearns & Co. is serving as managing book-runner for the offering and Lazard Capital Markets is co-manager.
The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.